Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02026843

Analysis of Biomarkers From Patients With Chorioretinal Diseases

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dong Ho Park

Daegu, Kyungsangpookdo, 700-721, South Korea

Location status: Recruiting

Location contact

Dong Ho Park, M.D

CONTACT

[email protected]

82-53-420-5813

About this study

This prospective, case-control study included 50 patients(50eyes) with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 patient with nondiabetic retinopathy or cataract. Ocular fluids and blood samples were taken before injection of anti-vascular endothelial growth factor agent or pars plana vitrectomy for other retinal disease. Ocular biomarkers were analyzed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age over 20 years
  • patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity.
  • patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
  • control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.

Exclusion criteria

  • under the age of 20 years
  • patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor
  • patients that did not signed the informed consent of the trial
  • patients with intraocular inflammations or infections that requiring any pharmaceutical agent
  • patients with recent ocular trauma

Treatment and study plan

Chorioretinal diseases

Drug

chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration

Primary outcomes

  1. Biomarkers in ocular fluids

    Time frame: one month

    To establish if certain type of chorioretinal diseases group are associated to different concentrations of gene or protein concentration.

Study contacts

Contact information is provided by the study sponsor or research team.

Dong Ho Park, M.D.

CONTACT

[email protected]

82-53-420-5813

Sponsors and collaborators

Lead sponsor

Kyungpook National University Hospital

Other

Registry information

Important dates

Study start
2012
Primary completion
2028
Study completion
2031
First posted
Jan 3, 2014
Registry last updated
Mar 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.